ConfiDisc Syringe Injection System granted U.S. patent

Product innovators Chris and Sonia Hillios are pleased to announce that they have been granted a patent by the U.S. Patent and Trademark Office pertaining to their new syringe injection system, ConfiDisc(R).

The patent covers the innovator's syringe injection system, which enables users to achieve the correct angle and depth of subcutaneous and intramuscular injections. The ConfiDisc(R) Syringe Injection System was developed for insulin and like medications and can be utilized in both home healthcare and professional medical settings. ConfiDisc(R) is an aid for injecting by syringe or pen needle. It provides added stability in both filling the syringe and during injection. ConfiDisc(R) has many benefits. It reduces pain perception and injection anxiety. ConfiDisc(R) enables users access to a larger range of injection sites, allowing better injection rotation. As a new hypodermic syringe, ConfiDisc(R) can greatly deter illegal intravenous drug use as it prevents injecting into a vein or artery.

This patent rewards the innovator's efforts to bring new technologies to the healthcare market. It grants ConfiDisc(R) intellectual property to the core functionality of its syringe injection system. The patent provides further security to ConfiDisc's(R) embodiments, which are recognized by the Federal Government.

There are more than 22 million diabetics in the United States alone. This makes up more than 7% of the U.S. population. Two-thirds of "at home" injections are self-administered. Injection anxiety is a proven cause of treatment failure, which leads to serious and life threatening complications. "We believe that our syringe injection system will greatly benefit all patients requiring daily injections. ConfiDisc(R) provides users the confidence they need and the comfort they deserve. ConfiDisc(R) is the next generation of syringe," said product developer, Chris Hillios.